Chlamydia in Testicular Tissue Linked to Male Infertility
|
By LabMedica International staff writers Posted on 26 Oct 2019 |

Image: The histological detection of chlamydia in human testicular biopsies (Photo courtesy of Queensland University of Technology).
Infectious diseases, such as mumps virus infection of the human testis, are known to play a role in spermatogenic dysfunction and have been associated with abnormal sperm parameters. Bacteria including Escherichia coli, mycoplasmas and Chlamydia trachomatis in human semen are also associated with abnormal sperm parameters.
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
Latest Microbiology News
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Channels
Clinical Chemistry
view channel
Blood Test Detects More High-Risk Prostate Cancers Than PSA
Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. Prostate-specific antigen (PSA) testing... Read more
Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
Rapid and accurate differentiation of stroke types remains a persistent challenge in emergency medicine, particularly because early imaging can miss ischemic events that require time-sensitive intervention.... Read moreMolecular Diagnostics
view channel
Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
Selecting adjuvant chemotherapy for hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer remains challenging because current genomic assays mainly estimate recurrence risk rather than predict... Read more
RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read morePathology
view channel
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read more
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Allograft rejection and chronic graft dysfunction remain major challenges in solid organ transplantation, requiring careful immunologic matching and long-term surveillance. Fragmented pre- and post-transplant... Read more
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








